Epithelial ovarian cancer in older women: defining the best management approach.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.14694/EdBook_AM.2015.35.e311PMID 25993191
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of ovarian cancer in the older woman.

  2015cited by this paper
• Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

  2014cited by this paper
• "Timed Up & Go": A Screening Tool for Predicting 30-Day Morbidity in Onco-Geriatric Surgical Patients? A Multicenter Cohort Study

  2014cited by this paper
• 3Geriatric assessment and tolerance to chemotherapy in elderly women with ovarian, primary peritoneal or fallopian tube cancer: A Gynecologic Oncology Group study

  2014cited by this paper
• Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

  2014cited by this paper
• CA125 Level Association With Chemotherapy Toxicity and Functional Status in Older Women With Ovarian Cancer

  2013cited by this paper
• Optimal Preoperative Assessment of the Geriatric Surgical Patient: A Best Practices Guideline From the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society

  2013cited by this paper
• Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial.

  2013cited by this paper
• Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)

  2013cited by this paper
• Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial.

  2013cited by this paper
• Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade

  2012cited by this paper
• A Phase 3 Trial of Bevacizumab in Ovarian Cancer

  2012cited by this paper
• Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

  2012cited by this paper
• Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society.

  2012cited by this paper
• Effect of Radical Cytoreductive Surgery on Omission and Delay of Chemotherapy for Advanced-Stage Ovarian Cancer

  2012cited by this paper
• Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.

  2011cited by this paper
• Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

  2011cited by this paper
• Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer.

  2011cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.

  2011cited by this paper
• Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer.

  2011cited by this paper
• Defining the limits of radical cytoreductive surgery for ovarian cancer.

  2011cited by this paper
• Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

  2011cited by this paper
• Thirty-Day Mortality After Primary Cytoreductive Surgery for Advanced Ovarian Cancer in the Elderly

  2011cited by this paper
• Epithelial ovarian cancer in the elderly: The memorial sloan‐kettering cancer center experience

  2010cited by this paper
• Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

  2010cited by this paper
• Ovarian cancer: Survival and treatment differences by age

  2010cited by this paper
• Regional variation in cancer‐directed surgery and mortality among women with epithelial ovarian cancer in the medicare population

  2010cited by this paper
• Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182).

  2010cited by this paper
• Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

  2009cited by this paper
• Ovarian cancer. Clinical practice guidelines in oncology.

  2008cited by this paper
• Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study.

  2008cited by this paper
• Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?

  2008cited by this paper
• Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study.

  2008cited by this paper
• Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

  2008cited by this paper
• Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction.

  2008cited by this paper
• A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.

  2008cited by this paper
• Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.

  2007cited by this paper
• Lung cancer in the elderly.

  2007cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.

  2007cited by this paper
• The management of recurrent ovarian cancer.

  2007cited by this paper
• Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.

  2007cited by this paper
• Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

  2007cited by this paper
• Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).

  2006cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006cited by this paper
• Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

  2006cited by this paper
• Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery.

  2006cited by this paper
• Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer.

  2006cited by this paper
• Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration

  2006cited by this paper
• Resource utilization for ovarian cancer patients at the end of life: how much is too much?

  2005cited by this paper
• Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients.

  2005cited by this paper
• Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.

  2005cited by this paper
• Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

  2004cited by this paper
• Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.

  2004cited by this paper
• Cancer in older persons: an international issue in an aging world.

  2004cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Weekly topotecan in the management of ovarian cancer.

  2003cited by this paper
• Morbidity of Cytoreductive Surgery in the Elderly

  2003cited by this paper
• Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma

  2002cited by this paper
• A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?

  2002cited by this paper
• Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden

  2002cited by this paper
• Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study.

  2002cited by this paper
• Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

  2002cited by this paper
• Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer.

  2002cited by this paper
• Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group.

  2000cited by this paper
• Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

  1999cited by this paper
• National survey of ovarian carcinoma IV: Patterns of care and related survival for older patients

  1994cited by this paper
• Lung cancer in the elderly.

  1994cited by this paper
• Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience.

  1993cited by this paper
• Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.

  1975cited by this paper

• Apoptotic effect of linifanib on human ovarian cancer OVCAR3 cell line

  2025cites this paper
• Impact of senescent fibroblasts secretome in ovarian cancer dissemination.

  2025cites this paper
• Advanced epithelial ovarian cancer in the older patient: a retrospective cohort study of six UK Gynaecological Cancer centers

  2025cites this paper
• Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification

  2025cites this paper
• Advanced epithelial ovarian cancer in older patients.

  2025cites this paper
• Optimising Chemotherapy for Advanced High-Grade Serous Ovarian Cancer via Delay-Differential Equations

  2025cites this paper
• Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer

  2025cites this paper
• First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature

  2024influential citation
• Factors affecting the long‐term prognosis of patients in the AYA generation with epithelial ovarian cancer: A multicenter propensity score matching analysis

  2024cites this paper
• Trends in gynecological cancer incidence, mortality, and survival among elderly women: A SEER study

  2024cites this paper
• The challenge of ovarian cancer care in the oldest old.

  2024cites this paper
• The pervasive impact of frailty on ovarian cancer care and the role of prehabilitation: Qualitative perspectives of key stakeholders

  2024cites this paper
• OSov: An Interactive Web Server to Evaluate Prognostic Biomarkers for Ovarian Cancer

  2021cites this paper
• The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank

  2021cites this paper
• A Rare Case of Mucinous Borderline Tumor in Adolescent Age Accompanied by Complete Vaginal Obstruction

  2019cites this paper
• Ovarian cancer: avoiding compromising quality of life during intense chemotherapy sessions

  2016cites this paper
• A case report of a young girl with mucinous borderline tumor of the ovary

  2016cites this paper
• Ovarian Cancer Treatment Decisions: Accessing Gynecologic Oncology Care

  2016cites this paper
• Case Report Introduction

  year unknowncites this paper